| Literature DB >> 34067207 |
Elisabetta Razzuoli1, Valeria Listorti1, Isabella Martini1, Laura Migone1, Lucia Decastelli2, Walter Mignone3, Enrica Berio3, Roberta Battistini4, Carlo Ercolini4, Laura Serracca4, Tiziana Andreoli5, Monica Dellepiane5, Daniela Adriano2, Monica Pitti2, Daniela Meloni2, Paola Modesto1.
Abstract
Salmonella spp. is an important zoonotic agent. Wild boars might host this pathogen in the intestinal tract and might represent a risk for Salmonella spp. transmission to humans. Wild boars are widely spread in Liguria, due to the environmental characteristics of the region. The aim of the study was the isolation, typing, and investigation of antimicrobial susceptibility of the isolated strains of Salmonella spp. During the 2013-2017 hunting seasons, 4335 livers of wild boars were collected and analyzed for the presence of Salmonella spp. A total of 260 strains of Salmonella spp. were isolated and characterized, with a prevalence of 6%. The isolated strains belonged to all six Salmonella enterica subspecies. Most of them were identified as Salmonella enterica subs. enterica of which 31 different serotypes were identified. The dominating serotype identified was S. Enteritidis. The antimicrobial resistance profiles of the isolated strains were analyzed against sixteen molecules. Of the isolated strains, 94.6% were resistant to at least one of the tested antimicrobials. This study showed the circulation of resistant Salmonella spp. strains in the wild boar population living in this area of Italy, underling the potential risk for these animals to disseminate this pathogen and its antimicrobial resistances.Entities:
Keywords: Salmonella spp.; antimicrobic resistance; wild boars
Year: 2021 PMID: 34067207 PMCID: PMC8151295 DOI: 10.3390/pathogens10050568
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Subspecies of S. enterica and serotypes of Salmonella enterica subs. enterica isolated.
| Isolated Serotypes or Subspecies | Number/260 | Percentage/Tot. |
|---|---|---|
| 5 | 1.9% | |
| 20 | 7.7% | |
| 10 | 3.8% | |
| 4 | 1.5% | |
| 3 | 1.2% | |
| 8 | 3.1% | |
| 21 | 8% | |
| 9 | 3.5% | |
| 3 | 1.2% | |
| 10 | 3.8% | |
| 8 | 3.1% | |
| 8 | 3.1% | |
| 7 | 2.7% | |
| 6 | 2.3% | |
| 5 | 1.9% | |
| 4 | 1.5% | |
| 6 | 2.3% | |
| 4 | 1.5% | |
| 3 | 1.2% | |
| 2 | 0.8% | |
| 2 | 0.8% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 1 | 0.4% | |
| 53 | 20.4% | |
| 13 | 5% | |
| 29 | 11.2% | |
| 7 | 2.7% | |
| 1 | 0.4% |
Percentage of isolated strain which resulted susceptible, intermediate, or resistant to the tested antimicrobials.
| Antibiotic | Susceptible | Intermediate | Resistant |
|---|---|---|---|
| Ampicillin | 206/260 (79.2%) | 29/260 (11.2%) | 25/260 (9.6%) |
| Amoxicillin + Clavulanic Acid | 171/217 (78.8%) | 33/217 (15.2%) | 13/217 (6%) |
| Chloramphenicol | 247/251 (98.4%) | 3/251 (1.2%) | 1/251 (0.4%) |
| Cefalotin | 197/260 (75.8%) | 47/260 (18%) | 16/260 (6.2%) |
| Cefotaxime | 235/258 (91%) | 20/258 (7.8%) | 3/258 (1.2%) |
| Ciprofloxacin | 258/260 (99.2%) | 2/260 (0.8%) | 0/260 (0%) |
| Colistin | 237/245 (96.7%) | 7/245 (2.9%) | 1/245 (0.4%) |
| Ceftazidime | 195/249 (78.3%) | 52/249 (20.9%) | 2/249 (0.8%) |
| Enrofloxacin | 190/207 (91.8%) | 16/207 (7.7%) | 1/207 (0.5%) |
| Gentamicin | 223/257 (86.8%) | 27/257 (10.5%) | 7/257 (2.7%) |
| Kanamycin | 118/230 (51.3%) | 99/230 (43%) | 13/230 (5.7%) |
| Nalidixic acid | 219/253 (86.6%) | 32/253 (12.6%) | 2/253 (0.8%) |
| Streptomycin | 106/258 (41%) | 78/258 (30.2%) | 28/258 (10.8%) |
| Sulfadiazine + Sulfamerazine + Sulfamethazine | 6/248 (2.4%) | 4/248 (1.6%) | 238/248 (96%) |
| Sulfamethoxazole + Trimethoprim | 153/260 (58.8%) | 50/260 (19.2%) | 57/260 (21.9%) |
| Tetracycline | 147/260 (56.5%) | 61/260 (23.4%) | 52/260 (20%) |
Antimicrobial resistance profile of multidrug-resistant strains (to 4 or more antimicrobials). In bold: antimicrobials considered “Highest Priority Critically Important”.
| Year | Strain | Antimicrobial Resistances |
|---|---|---|
| 2014 | A-AMC-KF-S-SSS-SXT-T | |
| 2014 | A-AMC-KF-S-SSS-SXT-T | |
| 2014 | A-AMC-KF-S-SXT-T | |
| 2014 | A-AMC-S-SSS-SXT-T | |
| 2013 | A-S-SSS-T | |
| 2013 | KF- | |
| 2015 | S-SSS-SXT-T | |
| 2013 | A-AMC-KF- | |
| 2013 | A-AMC-KF- | |
| 2013 | A-AMC-KF- | |
| 2013 | S-SSS-SXT-T | |
| 2013 | S-SSS-SXT-T | |
| 2013 | A-AMC-KF-SSS | |
| 2013 | A-AMC-KF-SSS-SXT-T | |
| 2016 | G-K-S-SSS-SXT-T | |
| 2016 | G-K-SSS-SXT-T | |
| 2016 | A-SSS-SXT-T | |
| 2016 | G-K-SSS-SXT-T | |
| 2013 | A-AMC-C-KF-SSS-SXT-T | |
| 2014 | A-KF-SSS-T | |
| 2016 | A-KF-S-SSS-SXT-T | |
| 2016 | G-K-S-SSS | |
| 2016 | ENR-G-K-SSS-SXT | |
| 2016 | G-K-SSS-SXT-T | |
| 2014 | S-SSS-SXT-T |
A: ampicillin, AMC: amoxicillin/clavulanic acid 2:1, C: chloramphenicol, KF: cefalotin, CTX: cefotaxime, CST: colistin, CAZ: ceftazidime, ENR: enrofloxacin, G: gentamicin, K: kanamycin, S: streptomycin, SSS: Sulfadiazine + Sulfamerazine + Sulfamethazine, SXT: trimethoprim-sulfamethoxazole, T: tetracycline.
Percentages of tested strains which showed antimicrobial resistances belonging to the most frequent serotypes of Salmonella spp. causing human illness in Europe. In bold: antimicrobials considered “Highest Priority Critically Important”.
|
|
| |||||||||||||||
| A | AMC | C | KF |
|
|
|
| ENR | G | K |
| S | SSS | SXT | T | |
| - * | - | - | - | - | - | - | - | - | - | - | - | - | 20/20 | 5/20 | 1/20 | |
| 1/10 | 1/9 | - | - | - | - | - | - | - | - | - | - | - | 6/6 | 3/10 | - | |
| 4/4 | 4/4 | - | 3/4 | - | - | - | - | - | - | - | - | 4/4 | 3/3 | 4/4 | 4/4 | |
| - | - | - | 1/3 | - | - | - | - | - | - | - | - | - | 3/3 | - | 1/3 | |
| - | - | - | - | - | - | - | - | - | - | - | 5/8 | 8/8 | 1/8 | - | ||
| 4/21 | - | - | - | - | - | - | - | - | - | - | - | 1/21 | 18/21 | - | 2/21 | |
| 1/9 | 2/9 | - | 1/9 | - | - |
|
| - | - | - | - | 2/9 | 9/9 | 2/9 | 6/9 | |
A: ampicillin, AMC: amoxicillin/clavulanic acid 2:1, C: chloramphenicol, KF: cefalotin, CTX: cefotaxime, CIP: ciprofloxacin, CST: colistin, CAZ: ceftazidime, ENR: enrofloxacin, G: gentamicin, K: kanamycin, NAL: nalidixic acid, S: streptomycin, SSS: Sulfadiazine + Sulfamerazine + Sulfamethazine, SXT: trimethoprim-sulfamethoxazole, T: tetracycline. - *: Resistance not observed.